Howard Sofen1, Kenneth G Gross2, Leonard H Goldberg3, Harry Sharata4, Tiffani K Hamilton5, Barbara Egbert6, Benjamin Lyons7, Jeannie Hou7, Ivor Caro7. 1. Department of Medicine/Dermatology, David Geffen School of Medicine at University of California-Los Angeles, Los Angeles, California. Electronic address: hsofen@ucla.edu. 2. Skin Surgery Medical Group Inc, San Diego, California. 3. DermSurgery Associates, Houston, Texas. 4. Madison Skin and Research Inc, Madison, Wisconsin. 5. Atlanta Dermatology, Vein and Research Center LLC, Atlanta, Georgia. 6. Stanford University Medical School, Stanford, California; Department of Veterans Affairs Palo Alto Health Care System, Palo Alto, California. 7. Genentech Inc, South San Francisco, California.
Abstract
BACKGROUND: Vismodegib is approved for treatment of advanced basal cell carcinoma. OBJECTIVE: We sought to characterize vismodegib efficacy and safety in operable basal cell carcinoma. METHODS: Patients with new, operable, nodular basal cell carcinoma received vismodegib (150 mg/d) followed by excision and Mohs micrographic surgery to ensure clear margins. Cohort 1 received vismodegib for 12 weeks; cohort 2 received vismodegib for 12 weeks, then 24 weeks of observation before excision; and cohort 3 received vismodegib for 8 weeks on/4 weeks off/8 weeks on. RESULTS: In all, 24 patients enrolled in cohort 1, and 25 in cohorts 2 and 3. Complete histologic clearance was achieved by 42%, 16%, and 44% of patients in cohorts 1, 2, and 3, respectively. Muscle spasms (76%), alopecia (58%), and dysgeusia (50%) were the most frequent adverse events (AEs). Five (7%) patients discontinued treatment because of an AE. AE reversibility was evaluated in cohort 2 with 24 weeks of observation after treatment discontinuation. LIMITATIONS: Nonrandomized, small cohort sizes, and short observation durations for some patients are limitations. CONCLUSION: Primary efficacy end points were not met (predefined complete histologic clearance rate: >50% in cohorts 1 and 3; >30% in cohort 2). Safety was comparable when dosed continuously versus intermittently. Posttreatment reversibility of vismodegib-related AEs was demonstrated.
BACKGROUND: Vismodegib is approved for treatment of advanced basal cell carcinoma. OBJECTIVE: We sought to characterize vismodegib efficacy and safety in operable basal cell carcinoma. METHODS:Patients with new, operable, nodular basal cell carcinoma received vismodegib (150 mg/d) followed by excision and Mohs micrographic surgery to ensure clear margins. Cohort 1 received vismodegib for 12 weeks; cohort 2 received vismodegib for 12 weeks, then 24 weeks of observation before excision; and cohort 3 received vismodegib for 8 weeks on/4 weeks off/8 weeks on. RESULTS: In all, 24 patients enrolled in cohort 1, and 25 in cohorts 2 and 3. Complete histologic clearance was achieved by 42%, 16%, and 44% of patients in cohorts 1, 2, and 3, respectively. Muscle spasms (76%), alopecia (58%), and dysgeusia (50%) were the most frequent adverse events (AEs). Five (7%) patients discontinued treatment because of an AE. AE reversibility was evaluated in cohort 2 with 24 weeks of observation after treatment discontinuation. LIMITATIONS: Nonrandomized, small cohort sizes, and short observation durations for some patients are limitations. CONCLUSION: Primary efficacy end points were not met (predefined complete histologic clearance rate: >50% in cohorts 1 and 3; >30% in cohort 2). Safety was comparable when dosed continuously versus intermittently. Posttreatment reversibility of vismodegib-related AEs was demonstrated.
Authors: Lan G Coffman; Yun-Jung Choi; Karen McLean; Benjamin L Allen; Marina Pasca di Magliano; Ronald J Buckanovich Journal: Oncotarget Date: 2016-02-09
Authors: Andrew Wiechert; Caner Saygin; Praveena S Thiagarajan; Vinay S Rao; James S Hale; Nikhil Gupta; Masahiro Hitomi; Anil Belur Nagaraj; Analisa DiFeo; Justin D Lathia; Ofer Reizes Journal: Oncotarget Date: 2016-05-24
Authors: Alon Kahana; Shelby P Unsworth; Christopher A Andrews; May P Chan; Scott C Bresler; Christopher K Bichakjian; Alison B Durham; Hakan Demirci; Victor M Elner; Christine C Nelson; Denise S Kim; Shannon S Joseph; Paul L Swiecicki; Francis P Worden Journal: Oncologist Date: 2021-05-31
Authors: Mario E Lacouture; Brigitte Dréno; Paolo Antonio Ascierto; Reinhard Dummer; Nicole Basset-Seguin; Kate Fife; Scott Ernst; Lisa Licitra; Rogerio I Neves; Ketty Peris; Susana Puig; Jonas Sokolof; Aleksandar Sekulic; Axel Hauschild; Rainer Kunstfeld Journal: Oncologist Date: 2016-08-10